CA2150477A1 - Ciblage sequentiel des sites tumoraux a l'aide de conjugues oligonucleotidiques d'anticorps et de conjugues oligonucleotidiques complementaires de radionucleides chelates - Google Patents
Ciblage sequentiel des sites tumoraux a l'aide de conjugues oligonucleotidiques d'anticorps et de conjugues oligonucleotidiques complementaires de radionucleides chelatesInfo
- Publication number
- CA2150477A1 CA2150477A1 CA002150477A CA2150477A CA2150477A1 CA 2150477 A1 CA2150477 A1 CA 2150477A1 CA 002150477 A CA002150477 A CA 002150477A CA 2150477 A CA2150477 A CA 2150477A CA 2150477 A1 CA2150477 A1 CA 2150477A1
- Authority
- CA
- Canada
- Prior art keywords
- residue
- precursor
- reagent
- oligonucleotide
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Optics & Photonics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98569992A | 1992-11-30 | 1992-11-30 | |
| US985699 | 1992-11-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2150477A1 true CA2150477A1 (fr) | 1994-06-09 |
Family
ID=25531717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002150477A Abandoned CA2150477A1 (fr) | 1992-11-30 | 1993-11-30 | Ciblage sequentiel des sites tumoraux a l'aide de conjugues oligonucleotidiques d'anticorps et de conjugues oligonucleotidiques complementaires de radionucleides chelates |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0680335A1 (fr) |
| JP (1) | JPH08503854A (fr) |
| AU (1) | AU5733994A (fr) |
| CA (1) | CA2150477A1 (fr) |
| WO (1) | WO1994012216A1 (fr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9207126A (pt) * | 1992-05-07 | 1995-08-29 | Sterling Winthrop Inc | Imunorreagente radioativo de marcação,composição formadora de imagem,composição terapêutica,processo para a formação de imagem diagnóstica em um sítio em um paciente e para tratar sítios de doença em um paciente,e,composição de matéria |
| US8063190B2 (en) * | 1998-06-02 | 2011-11-22 | Tom Robin Caine Boyde | Nucleic acid-linked conjugates and methods for making and using them |
| AR059193A1 (es) | 2006-01-31 | 2008-03-12 | Bayer Schering Pharma Ag | Modulacion de la actividad de mdl-1 para el tratamiento de enfermedades inflamatorias |
| JP2008297203A (ja) * | 2007-05-29 | 2008-12-11 | Chisso Corp | 複合体 |
| EP2005970A1 (fr) | 2007-06-22 | 2008-12-24 | Berlin Science Partners GmbH i.V. | Imagerie Diagnostique par combinaison de moyens de contraste |
| EP2072060A1 (fr) | 2007-12-18 | 2009-06-24 | Institut Curie | Procédés et compositions pour la préparation et l'utilisation de conjugués de toxines |
| AU2013302867A1 (en) | 2012-08-13 | 2015-02-26 | The Regents Of The University Of California | Methods and systems for detecting biological components |
| US10697007B2 (en) | 2014-06-27 | 2020-06-30 | The Regents Of The University Of California | PCR-activated sorting (PAS) |
| US10434507B2 (en) | 2014-10-22 | 2019-10-08 | The Regents Of The University Of California | High definition microdroplet printer |
| CN115011670A (zh) * | 2015-02-04 | 2022-09-06 | 加利福尼亚大学董事会 | 通过在离散实体中条形码化对核酸进行测序 |
| CN110088290A (zh) | 2016-08-10 | 2019-08-02 | 加利福尼亚大学董事会 | 在乳液微滴中结合多重置换扩增和pcr |
| CA3047328A1 (fr) | 2016-12-21 | 2018-06-28 | The Regents Of The University Of California | Sequencage genomique de cellules uniques a l'aide de gouttelettes a base d'hydrogel |
| US10501739B2 (en) | 2017-10-18 | 2019-12-10 | Mission Bio, Inc. | Method, systems and apparatus for single cell analysis |
| CA3138806A1 (fr) | 2019-05-22 | 2020-11-26 | Dalia Dhingra | Methode et appareil de sequencage cible simultane d'adn, d'arn et de proteine |
| WO2021003255A1 (fr) | 2019-07-01 | 2021-01-07 | Mission Bio | Procédé et appareil pour normaliser des lectures quantitatives dans des expériences à cellule unique |
| CN117867664B (zh) * | 2023-12-25 | 2024-11-26 | 康龙化成(宁波)科技发展有限公司 | 一种On-DNA亚磺酰亚胺类化合物及其合成方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4587044A (en) * | 1983-09-01 | 1986-05-06 | The Johns Hopkins University | Linkage of proteins to nucleic acids |
| IE914220A1 (en) * | 1990-12-10 | 1992-06-17 | Akzo Nv | Labelled, modified oligonucleotides |
-
1993
- 1993-11-30 CA CA002150477A patent/CA2150477A1/fr not_active Abandoned
- 1993-11-30 EP EP94903374A patent/EP0680335A1/fr not_active Withdrawn
- 1993-11-30 JP JP6513469A patent/JPH08503854A/ja active Pending
- 1993-11-30 AU AU57339/94A patent/AU5733994A/en not_active Abandoned
- 1993-11-30 WO PCT/US1993/011637 patent/WO1994012216A1/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JPH08503854A (ja) | 1996-04-30 |
| EP0680335A1 (fr) | 1995-11-08 |
| AU5733994A (en) | 1994-06-22 |
| WO1994012216A1 (fr) | 1994-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6248870B1 (en) | Unsymmetrical complexing agents and targeting immunoreagents useful in therapeutic and diagnostic compositions and methods | |
| CA2150477A1 (fr) | Ciblage sequentiel des sites tumoraux a l'aide de conjugues oligonucleotidiques d'anticorps et de conjugues oligonucleotidiques complementaires de radionucleides chelates | |
| CA2223261C (fr) | Apport ameliore d'agents diagnostiques ou therapeutiques a un site cible | |
| US5760191A (en) | Macrocyclic complexing agents and targeting immunoreagents useful in therapeutic and diagnostic compositions and methods | |
| EP0173629B1 (fr) | Complexes d'ions métalliques conjugés avec des anticorps | |
| JP3292301B2 (ja) | 治療用及び診断用撮像組成物及び方法において役立つ錯化剤及びターゲティング放射性免疫試薬 | |
| US5733523A (en) | Targeted delivery of a therapeutic entity using complementary oligonucleotides | |
| RU2122431C1 (ru) | Радиоактивный иммунореагент направленного действия, композиция для получения изображения злокачественного новообразования в организме, способ получения изображения и комплексообразующий агент | |
| CA2157902A1 (fr) | Ciblage de tumeurs a l'aide de conjugues d'oligonucleotide l-enantiomeres d'immunoreactifs et de radionucleides chelates | |
| JP3143506B2 (ja) | 治療用物質の標的送達用医薬組成物 | |
| EP0675737A1 (fr) | Reactifs a reactivite immunologique utilisant la dihydrofolate reductase | |
| AU7244894A (en) | Immunoreactive reagents employing monoamine oxidase | |
| AU6128694A (en) | Immunoreactive reagents employing heterodimers | |
| WO1997033626A1 (fr) | Nouveaux chelateurs et compositions preparees a l'aide de ceux-ci | |
| US7713528B1 (en) | Method for in vivo delivery of active compounds using reagent conjugate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |